NCT04797468撤回1 期
A Phase 1 Clinical Study to Investigate the Safety, Tolerability and to Determine the Maximum Tolerated Dose and Recommended Phase 2 Dose of HLX23 (CD73 Inhibitor) in Patients With Advanced or Metastatic Solid Tumors
Shanghai Henlius Biotech1 个研究点 分布在 1 个国家开始时间: 2022年7月18日最近更新:
适应症
干预措施
试验速览
- 阶段
- 1 期
- 状态
- 撤回
- 发起方
- 试验地点
- 1
- 主要终点
- Number of Participants with Dose Limiting Toxicity
研究概览
简要总结
The reason for this study is to see if the CD73 inhibitor HLX23 alone is safe and effective in participants with advanced solid cancer.
详细描述
An open-label, dose escalation, first-in-human, phase 1 clinical study to investigate the safety, tolerability and to determine the maximum tolerated dose and recommended phase 2 dose of HLX23 (recombinant anti-CD73 humanized monoclonal antibody) in patients with advanced or metastatic solid tumors
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Volunteer to participate, fully understand the study and have signed the ICF, willing and have the capacity to comply with and complete all trial procedures;
- •Aged ≥ 18 years when signing the ICF;
- •Patients with advanced or metastatic solid tumors confirmed by histologically or cytologically, who have failed standard treatment, or who do not have standard treatment regimens, or who are not suitable for standard treatment;
- •Patients with at least one evaluable lesion assessed as per RECIST1.1 criteria;
- •Patients must be able to supply adequate tumor tissue for biomarker (CD73 and CD68 ) analyses;
- •Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 when enrolled in the study;
- •Life expectancy longer than three months;
- •Adequate hematologic functions;
- •Adequate hepatic function ;
- •Adequate renal function, as defined by the creatinine clearance rate ≥ 50 mL/minute by Cockcroft-Gault formula;
- •Adequate cardiac function ;
- •At least 28 days from prior major surgery or medical device or local radiotherapy, at least five half-lives from prior cytotoxic chemotherapy, immunotherapy, biological agents and at least 14 days from prior hormonal therapy and minor surgery before the first infusion of HLX23;
- •For patients with hepatocellular carcinoma, the Child-Pugh score has to be A;
- •Female participants of childbearing potential and male partners with female partners of childbearing potential must agree to use one adequate and medically approved barrier method of contraception during the study and for at least 6 months after the last dose of the study drugs.
- •Exclusion criteria:
- •Patients who still have ≥ grade 2 toxicities from prior therapies;
- •Patients who have history of allergic reaction to monoclonal antibodies;
- •Concurrent unstable or uncontrolled medical conditions;
- •Any concurrent malignancy other than basal cell carcinoma or carcinoma in situ of the cervix (patients with previous history of malignancy but without evidence of disease for ≥ 3 years can participate in the study);
- •History of prior treatment with anti-CD73 antibodies,including patients treated with adenosine receptor antagonists, CD39 or CD73 inhibitors ;
- •Patients with active autoimmune disease, except vitiligo or cured childhood asthma/allergies that requires no intervention after adulthood, autoimmune-mediated hypothyroidism treated with stable doses of thyroid hormone replacement, or Type I diabetes treated with stable doses of insulin can be excepted. Patients in a stable state and do not require systemic immunosuppressive therapy (including corticosteroids) are allowed to be enrolled;
- •Pregnancy or breast-feeding;
- •Known history of human immunodeficiency virus infection (HIV), but the patients with CD4+ T-cell (CD4+) counts ≥ 350 cells/uL are allowed to be enrolled.
- •hepatitis B virus carrier status (HBV surface antigen positive) and hepatitis C carrier (anti-HCV antibody positive). If HBsAg (+) or HBcAb (+), the HBV-DNA≥2500copy/mL or 500 IU/mL, or clinically judged active hepatitis; Subjects co-infected with hepatitis B and hepatitis C should be excluded (positive HBsAg or HBcAb test and positive HCV antibody test);
- •The patient is the investigator, sub-investigator or anyone directly involved in the conduct of the study;
- •History or current evidence of any condition or disease that could confound the results of the study, or participation is not in the best interest of the patient in the opinion of the Investigator(s).
排除标准
- 未提供
研究组 & 干预措施
HLX23
Experimental
HLX23 administered IV.
干预措施: HLX23 (Drug)
结局指标
主要结局
Number of Participants with Dose Limiting Toxicity
时间窗: Up to 21 Days
DLT
maximum tolerated dose of HLX23
时间窗: Up to 21 Days
MTD
Recommended phase 2 dose of HLX23
时间窗: Up to 21 Days
RP2D
次要结局
- Pharmacodynamic(PD)(cycle 1, cycle 2, cycle 3 (one week is a cycle) to day 30 after the last dose)
- Disease Control Rate (DCR)(Baseline through Measured Progressive Disease (Estimated at up to 2 Years))
- Immunogenicity(cycle 1, cycle 2, cycle 4, cycle 6 to day 30 after the last dose)
- Pharmacokinetics(PK)(cycle 1 (one week is a cycle) to day 30 after the last dose)
- Overall Response Rate (ORR)(Baseline through Disease Progression or Death (Estimated at up to 2 Years))
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Guselkumab (Anti-IL 23 Monoclonal Antibody) for Alcohol Associated Liver DiseaseAlcoholic Liver DiseaseNCT04736966University of California, San Diego13
招募中
2 期
A Phase II Clinical Study to Evaluate HLX43 in Patients With Locally Advanced or Metastatic HCC Failed or Intolerance to Standard TherapyCarcinoma, HepatocellularNCT06742892Shanghai Henlius Biotech90
已完成
1 期
Anti-CD137 and Anti-CTLA-4 Monoclonal Antibody in Patients With Advanced CancerAdvanced CancerNCT04121676Agenus Inc.91
已完成
1 期
A Study of the CD73 Inhibitor LY3475070 Alone or in Combination With Pembrolizumab in Participants With Advanced CancerAdvanced CancerNCT04148937Eli Lilly and Company52
招募中
1 期
A Clinical Research About CD70-positive Advanced/Metastatic Solid Tumors Treated by CD70-targeted CAR-TMetastatic TumorAdvanced Solid TumorCervix CancerOvarian CancerRenal Cell CarcinomaNCT05468190Chongqing Precision Biotech Co., Ltd48